Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > British Columbia Securities Commission!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(40)
•••
Comment by zwerp2000on Feb 07, 2023 1:48pm
140 Views
Post# 35272318

RE:RE:RE:RE:RE:RE:RE:British Columbia Securities Commission!!

RE:RE:RE:RE:RE:RE:RE:British Columbia Securities Commission!!Rathjen has been a complete failure. 

1. Go back and listen to some of her speeches at previous annual shareholder meetings. Nothing she claimed would happen came true. Not even close

2. No drugs in the clinic

3. No progress with any of their programs

4. Received very little money from Chiesi a few years ago and it doesn't seem like anything is happening there. Deal was signed years ago and nothing

5. Prothena is gone

6. Company desperately tried to save itself by selling out for peanuts to MTP. This was rejected by MTP shareholders. Oh and MTP is pretty much bankruptcy themselves as they can't pay the cancellation fee. LOL

7. Company has no money. Trades at $.03 and is about to go bankrupt.

8. Rathjen received decent compensation for doing nothing for this company. What has she accomplished other than presiding over another company about to go bankrupt. 


Yes, great job Doc! Good call prophetofabsurdity
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities